Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of Acute Respiratory Distress Syndrome (RAPA-CARDS)
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Sirolimus (Primary)
- Indications Acute lung injury; Adult respiratory distress syndrome; COVID 2019 infections
- Focus Therapeutic Use
- Acronyms RAPA-CARDS
- 27 May 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 08 Feb 2021 Planned initiation date changed from 1 Jan 2021 to 1 Apr 2021.
- 25 Nov 2020 Planned End Date changed from 1 Oct 2022 to 1 Jan 2023.